Progression on Ibrutinib With the Acquisition of Resistance Mutations
Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the association of disease progression on ibrutinib therapy with the acquisition of resistance mutations as seen at The Ohio State University Comprehensive Cancer Center.
Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the association of disease progression on ibrutinib therapy with the acquisition of resistance mutations as seen at The Ohio State University Comprehensive Cancer Center.
Clinical Pearls:
- Researchers found that the 267 patients that were treated with ibrutinib at The Ohio State University Comprehensive Cancer Center had a low rate of relapse.
- 29 patients were in total relapse with a median follow-up of 20 months. Of those 29 patients, 17 relapsed with Richter's transformation while the other 12 relapsed with CLL.
- Patients who relapsed with CLL also had BTK and PLCγ2 mutations that were not present at baseline.
- Only 2 out of 8 patients tested who relapsed with Richter’s transformation had mutations in BTK or PLCγ2.
- Further research is being conducted to look into the associated between Richter’s transformation and BTK and PLCγ2 mutations.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
